Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.

摘要: Monoclonal antibodies have expanded our cancer-fighting armamentarium in both the United States and Europe. While general, monoclonal are well tolerated do not significant overlapping side effects with traditional cytotoxic agents, severe infusion reactions (IRs)--sometimes enough to be life threatening--have been reported. The pathophysiology of associated is poorly understood, but mechanisms beginning elucidated. Geographic differences incidence IRs become apparent. Understanding risk, recognizing signs symptoms, being ready promptly manage key for clinician avoid unnecessarily discontinuing these effective anticancer agents prevent potentially tragic consequences their patients. To date, clinical trials incorporated into combinations standard regimens; it expected that time will testing promising new utilizing multiple targeted resulting improved toxicity profiles efficacy cancer